Section Arrow
Quote
ONC.NASDAQ
- BeOne Medicines Ltd
Quotes are at least 15-min delayed:2026/08/31 17:09 EDT
After Hours
Last
 362.3
+2.72 (+0.76%)
Bid
359.17
Ask
359.57
High 375 
Low 359.58 
Volume 46.12K 
Regular Hours (Closed)
Last
 359.58
-7.15 (-1.95%)
Day High 
361.03 
Prev. Close
366.73 
1-M High
380 
Volume 
344.08K 
Bid
359.17
Ask
359.57
Day Low
352.86 
Open
356.5 
1-M Low
309.935 
Market Cap 
41.49B 
Currency 美元 
P/E 65.6 
%Yield -- 
10-SMA 371.55 
20-SMA 356.94 
50-SMA 324.98 
52-W High 385.22 
52-W Low 253.9475 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
5.59/9.93
Enterprise Value
42.50B
Balance Sheet
Book Value Per Share
45.74
Cash Flow
Cash Flow Yield
0.04
Income Statement
Total Revenue
5.34B
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CLGNCollPlant Biotechnologies Ltd0.3879+0.0299+8.35%-- 
After Hours 0.3666 -0.0213 -5.49%
AIMAIM ImmunoTech Inc.0.226-0.0324-12.54%-- 
After Hours 0.2315 +0.0055 +2.43%
ROIVRoivant Sciences Ltd34.64-0.07-0.20%-- 
After Hours 35.8942 +1.2542 +3.62%
CVKDCadrenal Therapeutics Inc1.75+0.21+13.64%-- 
After Hours 1.6 -0.15 -8.57%
MRNAModerna140.34+2.35+1.70%-- 
After Hours 139.0767 -1.2633 -0.90%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugsin its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.